The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11 results:
Author Title [ Type(Desc)] Year
Filters: Keyword is Receptors, Estrogen and Author is Fountzilas, George  [Clear All Filters]
Journal Article
Stevens, K. N., Fredericksen Z., Vachon C. M., Wang X., Margolin S., Lindblom A., et al. (2012).  19p13.1 is a triple-negative-specific breast cancer susceptibility locus.. Cancer Res. 72(7), 1795-803.
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
Stevens, K. N., Vachon C. M., Lee A. M., Slager S., Lesnick T., Olswold C., et al. (2011).  Common breast cancer susceptibility loci are associated with triple-negative breast cancer.. Cancer Res. 71(19), 6240-9.
Haiman, C. A., Chen G. K., Vachon C. M., Canzian F., Dunning A., Millikan R. C., et al. (2011).  A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.. Nat Genet. 43(12), 1210-4.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Batistatou, A., Televantou D., Bobos M., Eleftheraki A. G., Kouvaras E., Chrisafi S., et al. (2013).  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.. Anticancer Res. 33(5), 2139-45.
Pentheroudakis, G., Kalogeras K. T., Wirtz R. M., Grimani I., Zografos G., Gogas H., et al. (2009).  Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.. Breast Cancer Res Treat. 116(1), 131-43.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Antoniou, A. C., Wang X., Fredericksen Z. S., McGuffog L., Tarrell R., Sinilnikova O. M., et al. (2010).  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.. Nat Genet. 42(10), 885-92.
Gogas, H., Pectasides D., Kostopoulos I., Lianos E., Skarlos D., Papaxoinis G., et al. (2010).  Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.. Clin Breast Cancer. 10(3), 230-7.
Fostira, F., Tsitlaidou M., Papadimitriou C., Pertesi M., Timotheadou E., Stavropoulou A. V., et al. (2012).  Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.. Breast Cancer Res Treat. 134(1), 353-62.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.